Trial Profile

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 17 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glecaprevir/pibrentasvir (Primary) ; Opioid receptor agonists
Indications Hepatitis C; Recurrence
Focus Therapeutic Use
Acronyms ECLIPSE

Most Recent Events

30 Apr 2021 Status changed from not yet recruiting to withdrawn prior to enrolment as Department of Corrections unable to support study at this time and find agreement on publication issue.
22 Apr 2021 Planned End Date changed from 30 Mar 2023 to 30 Oct 2024.
22 Apr 2021 Planned primary completion date changed from 30 Aug 2021 to 30 Mar 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com